WO2011002179A2 - 복분자 추출물을 함유하는 피부 주름 개선용 화장료 조성물 - Google Patents
복분자 추출물을 함유하는 피부 주름 개선용 화장료 조성물 Download PDFInfo
- Publication number
- WO2011002179A2 WO2011002179A2 PCT/KR2010/004144 KR2010004144W WO2011002179A2 WO 2011002179 A2 WO2011002179 A2 WO 2011002179A2 KR 2010004144 W KR2010004144 W KR 2010004144W WO 2011002179 A2 WO2011002179 A2 WO 2011002179A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- bokbunja
- extract
- cosmetic composition
- skin wrinkles
- present
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/805—Corresponding aspects not provided for by any of codes A61K2800/81 - A61K2800/95
Definitions
- the present invention relates to a cosmetic composition containing a bokbunja extract as an active ingredient, and more particularly, by containing a bokbunja extract processed by using the herbal medicine processing agent, inhibits the formation of the SNARE complex and inhibits the release of neurotransmitter skin
- the present invention relates to a cosmetic composition having an excellent effect of improving wrinkles.
- the cosmetic composition of the present invention has excellent stability in formulations compared to existing skin wrinkle improvers, and exhibits a similar effect to Botox that has been used in conventional wrinkle improvement procedures, thereby greatly improving skin wrinkles without side effects.
- the synaptic vesicle containing the neurotransmitter When the neurotransmitter is discharged, the synaptic vesicle containing the neurotransmitter must be fused with the presynaptic membrane to form a pathway between the two boundaries.
- the protein that provides the fundamental force of membrane fusion is three protein complexes called SNARE (soluble N-ethylmaleimide-sensitive factor attachment protein receptor).
- SNARE soluble N-ethylmaleimide-sensitive factor attachment protein receptor
- Membrane fusion between the synaptic vesicles and the presynaptic membrane opens the neurotransmitter pathway, involving the t-SNARE complex attached to the target membrane and the v-SNARE attached to the vesicle.
- t-SNARE is a complex of a protein called Syntaxin 1a and a protein called SNAP-25. These SNARE proteins are twisted like pretzel.
- the membrane fusion results in rearrangement of lipid bilayers, which are well known in the art.
- Biofilms are strongly pushed against each other, so these membranes are not spontaneously fused and have a strong force from outside to overcome the repulsion between the membranes.
- the formation of the SNARE complex is a source of force to overcome the intermembrane repulsive force, and is a key phenomenon of exocytosis including the release of neurotransmitters.
- the nerve terminal (nerve terminal) is loaded with synaptic vesicles.
- BoNT Botulinum neurotoxin, abbreviated as Botox
- Botox is a protease that cleaves SNARE protein, a key protein involved in neurotransmitter release. Botox cleaves SNARE proteins, blocking neurotransmission and consequently paralyzing the muscle cells that Botox has infiltrated. Whereas botox blocks neurotransmission by irreversibly cutting the SNARE protein, the so-called “coating botox” is a kind of "competitive inhibitor” that inhibits neurotransmission by inhibiting the formation of the SNARE complex.
- Argireline the main ingredient of current Botox products, has a weakness that its effects are uncertain, its price is disadvantageous due to the nature of synthetic peptides, and it is not consumer friendly.
- Developing neurotransmission suppression using natural extracts can provide significantly cheaper raw materials than peptide materials, and because it is a natural product, it is more accessible to consumers when developing the final product. do.
- the traditional method of herbal medicine is said to be a traditional pharmaceutical technology, such as merger, agreement, shame, spores, legislation and investigation.
- This is a pharmaceutical technology that changes the original properties of the medicine by processing the medicine based on the herbal theory.
- Foam is a term that includes the selection of the correct form of a drug, detoxification, purification, heat treatment, and processing with aids.
- the sieve is added together with a supplement, to meet the needs of the medical care, and to achieve the purpose of the medication according to the dialectic.
- Different types of treatments are used for the drug preparation, and therefore have different properties and actions, and thus the action of the drug entrained is different.
- supplements There are many types of supplements currently used, which can be largely divided into liquid supplements and solid supplements.
- Liquid supplements include alcohol, vinegar, brine, honey, ginger juice, licorice juice, black bean juice, saline solution, unsweetened water, horse oil, milk, stool or lime water.
- Solid ingredients include rice, bran, alum, tofu, soil, flour or sand.
- the purpose of taking herbal medicines is to keep the drug clean, to facilitate storage, to reduce or eliminate the toxicity and side effects of the drug, to change the drug to make the drug more effective, to enhance the therapeutic effect of the drug, This is to get rid of bad smell and taste so that it can be taken well.
- Wrinkles in the skin are the most pronounced skin aging manifestations caused by endogenous factors such as age and stress, or external environmental factors such as air pollution or ultraviolet radiation. Wrinkles occur on the face, neck, neck, elbows, armpits, hands, and feet on the forehead, around the eyes, between the legs, and around the mouth. Most are noticeable around 30 years of age, and their number, depth and range increase with age.
- the main cause of wrinkle formation is that reactive oxygen species generated in skin tissues by skin aging process form crosslinks in collagen fibers and elastic fibers, which occupy most of the skin dermis constituents, and change the formation and decomposition of these fibers. can do.
- Antioxidants such as vitamin E, beta-carotene, vitamin C, and glutathione used to inhibit skin aging, and substances that enhance dermal collagen synthesis, such as radical scavengers and vitamin A, have been used to improve skin wrinkles. It has been used as a substance. However, most of these cosmetic active ingredients have strong skin irritation or are unstable in the formulation itself, resulting in discoloration, discoloration, and precipitation, and the inherent activity of raw materials is reduced.
- the present inventors have studied the natural raw materials having an excellent skin wrinkle improvement effect, when manufacturing a cosmetic composition using the bokbunja extract was found to have excellent skin wrinkle improvement effect and completed the present invention.
- the present invention provides a cosmetic composition for improving skin wrinkles containing bokbunja extract as an active ingredient.
- Cosmetic composition according to the present invention by inhibiting the formation of the SNARE complex and preventing the release of neurotransmitters by containing the bokbunja extract as an active ingredient is not only excellent effect to improve skin wrinkles, but also less side effects to the skin using natural materials Reduces skin irritation In addition, it is excellent in the stability of the formulation compared to the existing skin wrinkle improvers, and exhibits a similar effect to the Botox that has been used in the conventional wrinkle improvement procedure to greatly improve the wrinkles of the skin without side effects.
- 1 is a graph showing the inhibitory effect of the membrane fusion phenomenon by the bokbunja extract according to the present invention.
- Figure 2 is a graph showing the neurotransmitter release inhibitory effect in PC12 cells by the bokbunja extract according to the present invention.
- the present invention provides a cosmetic composition for improving skin wrinkles containing bokbunja extract as an active ingredient.
- the bokbunja (Rubus coreanus) used in the present invention is a fruit of the bokbunja strawberry (Rubus coreanus Miquel), has no smell, taste is sweet and sweet and warm properties.
- Bokbunja boosts renal function and is used in oil wells, dreams, and urination. It is used for weakening eyesight, lightens the body and makes the head black. It also helps a woman conceive and tender and beautiful skin. As pharmacological action, anti-inflammatory action, antioxidant action and anti-helicobacter pylori action have been reported.
- Bokbunja of the present invention inhibits the formation of a soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) complex and inhibits the release of neurotransmitters. This exhibits an effect similar to that of Botox, which has been conventionally used for skin wrinkle improvement procedures, and can greatly improve wrinkles of the skin without side effects.
- SNARE N-ethylmaleimide-sensitive factor attachment protein receptor
- the bokbunja extract according to the present invention may be treated with foam before extracting the bokbunja with a solvent.
- Bokbunja is treated by boiling, steaming, roasting, roasting, or mixing them. More specifically, when boiled 60 ⁇ 100 °C, 30 minutes ⁇ 2 hours / steaming 120 ⁇ 150 °C, 3 ⁇ 6 hours / when roasting 100 ⁇ 180 °C, 10 minutes ⁇ 1 hour / when baking 80 ⁇ 100 °C, It is easily selected from 10 minutes to 1 hour. If the treatment temperature and the treatment time are out of range, the effect of the foam treatment may be lowered or a change of components may occur.
- liquor vinegar, brine, honey, ginger juice, licorice juice, black bean juice, saline solution, unsweetened water, horse oil, milk, stool, lime water, rice, bran , Alum, tofu, soil, flour or sand.
- Extraction of bokbunja of the present invention can be carried out by conventional methods known in the art. For example, water or an organic solvent is added to a foam-treated bokbunja, reflux extraction and deposition are carried out, the residue and the filtrate are separated by filtration and centrifugation of the filter cloth, and the separated filtrate is concentrated under reduced pressure to obtain a bokbunja extract.
- the organic solvent usable in the present invention may be selected from ethanol, methanol, butanol, ether, ethyl acetate, chloroform or a mixed solvent of these organic solvents and water, and preferably 80% ethanol is used.
- the extraction temperature is preferably 10 ⁇ 80 °C
- the extraction time is preferably 6 ⁇ 24 hours. If the extraction temperature and the extraction time is out of the extraction efficiency may be lowered or a change of components may occur.
- the cosmetic composition according to the present invention contains the bokbunja extract in an amount of 0.0001 to 30% by weight based on the total weight of the composition. This is because if the content is less than 0.0001% by weight, the skin wrinkle improvement effect cannot be obtained, and if the content is more than 30% by weight, the increase in effect is not large.
- the cosmetic composition according to the present invention may be formulated as a flexible lotion, astringent lotion, nourishing lotion, nourishing cream, massage cream, essence, pack, foundation, lipstick or powder foundation, but is not limited thereto.
- 1kg of dried bokbunja is mixed well with 200ml of brine (aged using traditional Onggi in cool shade, and the brine concentration is 8 ⁇ 10% and 20 ⁇ 30% of the dry weight of bokbunja) and sealed to be completely absorbed.
- the bokbunja which had been completely absorbed by the brine, was placed in a herb container at 150 ° C., then roasted for 30 minutes, and dried in the shade.
- 5 L of an 80% ethanol aqueous solution was added thereto, followed by extraction under reflux three times, followed by immersion at 15 ° C for 1 day. Thereafter, the residue and the filtrate were separated through filter cloth filtration and centrifugation. The separated filtrate was concentrated under reduced pressure to obtain 295 g of Bokbunja salt extract.
- SNARE proteins called SNAP25 (NMO11428), Trustsin 1a (AF217197) and VAMP2 (NMO12663) were purified from E. coli Codon (+) RIL, Novagen transformed by biological techniques, respectively. .
- palmitoyl oleoyl phosphatidylcholine (POP) (62 mol%)
- dioleoyl phosphatidylserine (DOPS) 35 mol%)
- POP palmitoyl oleoyl phosphatidylcholine
- DOPS dioleoyl phosphatidylserine
- the mixture was mixed so that the molar concentration was 1: 1 and reacted at room temperature for 1 hour, and then mixed with a liposomal unlabeled fluorescent material so that the molar ratio was 100: 1.
- VAMP2 was bound to a molar ratio of 50: 1 with the liposome containing the fluorescent material.
- the two types of lyposomes were subjected to dialysis with stirring at 4 ° C. for 24 hours using a 10 kDa dialysis membrane, followed by mixing at a ratio of 3: 7 (v-vesicle: t-vesicle), SNAP-25, and trust.
- fluorescence intensity in FIG. 1 means membrane fusion between SNARE proteins, low fluorescence intensity indicates an excellent membrane fusion inhibitory effect.
- the black circle represents the path through which the control reaction proceeds.
- the bokbunja extract has a lower fluorescence intensity than the control group was found to have an effect of inhibiting the membrane fusion between SNARE proteins, in particular bokbunja main jeokje extract (Example 3) was inhibited membrane fusion than other experimental groups The effect was excellent.
- the fluorescence intensity of the control group was set as a reference and the relative percent membrane fusion inhibition in bokbunja extract was calculated. The results are shown in Table 1 below.
- the group treated with bokbunja extract was superior to the membrane fusion inhibitory effect than the control group does not contain the bokbunja extract, bokbunja main jeokje extract of Example 3 compared to the other bokbunja extract inhibition It was confirmed that the effect was excellent. Therefore, the bokbunja extract of the present invention can exhibit an excellent skin wrinkle improvement effect by effectively inhibiting the membrane fusion between SNARE proteins.
- PC12 cells were cultured in a collagen coated plate (60 mm dish) in Ham's F12K medium containing 10% fetal calf serum, 5% fetal bovine serum and antibiotics. Subculture is inhaled medium, pipetted with 2 ml of PBS and pipetted to separate the cells from the dish wall, centrifuged at 1,000 xg for 5 minutes to collect the cells, and then pipetted with fresh medium to disperse the cell pellet. and placed in a fresh culture plate and cultured in the incubator is 37 °C, CO 2 gas of 5% is supplied. [ 3 H] -noradrenaline used in the experiment was purchased from Amersham.
- Bokbunja main jeokje extract of Example 3 has a relatively high inhibitory effect of the release of neurotransmitters Appeared. Therefore, the bokbunja extract of the present invention can exhibit an excellent skin wrinkle improvement effect by inhibiting the release of neurotransmitters.
- a nourishing lotion containing Bokbunja syrup extract was prepared with the composition shown in Table 2 below.
- Example 3 5.0 Squalane 5.0 Beeswax 4.0 Polysorbate 60 1.5 Sorbitan sesquioleate 1.5 Liquid paraffin 0.5 Caprylic / Capric Triglycerides 5.0 glycerin 3.0 Butylene glycol 3.0 Propylene glycol 3.0 Carboxy Vinyl Polymer 0.1 Triethanolamine 0.2 Preservative, coloring, flavoring Quantity Purified water Remaining amount Sum 100
- a flexible lotion containing Bokbunja syrup extract was prepared with the composition shown in Table 3 below.
- Example 3 5.0 glycerin 3.0 Butylene glycol 2.0 Propylene glycol 2.0 Carboxy Vinyl Polymer 0.1 PEG 12 nonylphenyl ether 0.2 Polysorbate 80 0.4 ethanol 10.0 Triethanolamine 0.1 Preservative, coloring, flavoring Quantity Purified water Remaining amount Sum 100
- Nourishing cream containing Bokbunja syrup extract was prepared with the composition shown in Table 4 below.
- Example 3 5.0 Polysorbate 60 1.5 Sorbitan sesquioleate 0.5 PEG60 Cured Castor Oil 2.0 Liquid paraffin 10.0 Squalane 5.0 Caprylic / Capric Triglycerides 5.0 glycerin 5.0 Butylene glycol 3.0 Propylene glycol 3.0 Triethanolamine 0.2 Preservative, coloring, flavoring Quantity Purified water Remaining amount Sum 100
- Example 3 5.0 Beeswax 10.0 Polysorbate 60 1.5 Sorbitan sesquioleate 0.8 PEG60 Cured Castor Oil 2.0 Liquid paraffin 40.0 Squalane 5.0 Caprylic / Capric Triglycerides 4.0 glycerin 5.0 Butylene glycol 3.0 Propylene glycol 3.0 Triethanolamine 0.2 Preservative, coloring, flavoring Quantity Purified water Remaining amount Sum 100
- a pack containing Bokbunja syrup extract was prepared with the composition shown in Table 6 below.
- Example 3 5.0 Polyvinyl alcohol 13.0 Sodium Carboxymethyl Cellulose 0.2 glycerin 5.0 Allantoin 0.1 ethanol 6.0 PEG 12 nonylphenyl ether 0.3 Polysorbate 60 0.3 Preservative, coloring, flavoring Quantity Purified water Remaining amount Sum 100
- Cosmetic composition containing Bokbunja chimju extract having the composition of Formulation Example 3 was applied to 12 women over 40 years old (average age 44.5 years) for 12 weeks around wrinkled eyes (2 times / day, 0.2 g / Times) Prior to cosmetic application (T 0 ) and 12 weeks after cosmetic application (T 12 ) through the objective evaluation of subjects and subjective evaluation of the subject by classifying according to the seventh grade according to the criteria score table in Table 7 to improve the improvement of skin wrinkles ( ⁇ W) was measured. The results are shown in Tables 8 to 9 below.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Birds (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
시료명 | 막 융합 저해율(%) | |
대조군(Control) | 100 | |
실시예 1 | 복분자 생품 추출물 | 51 |
실시예 2 | 복분자 청초 추출물 | 48 |
실시예 3 | 복분자 주증 추출물 | 0 |
실시예 4 | 복분자 염자 추출물 | 53 |
성분 | 함량(중량%) |
실시예 3 | 5.0 |
스쿠알란 | 5.0 |
밀납 | 4.0 |
폴리솔베이트 60 | 1.5 |
솔비탄세스퀴올레이트 | 1.5 |
유동파라핀 | 0.5 |
카프릴릭/카프릭트리글리세라이드 | 5.0 |
글리세린 | 3.0 |
부틸렌글리콜 | 3.0 |
프로필렌글리콜 | 3.0 |
카르복시비닐폴리머 | 0.1 |
트리에탄올아민 | 0.2 |
방부제, 색소, 향료 | 적량 |
정제수 | 잔량 |
합계 | 100 |
성분 | 함량(중량%) |
실시예 3 | 5.0 |
글리세린 | 3.0 |
부틸렌글리콜 | 2.0 |
프로필렌글리콜 | 2.0 |
카르복시비닐폴리머 | 0.1 |
PEG 12 노닐페닐에테르 | 0.2 |
폴리솔베이트 80 | 0.4 |
에탄올 | 10.0 |
트리에탄올아민 | 0.1 |
방부제, 색소, 향료 | 적량 |
정제수 | 잔량 |
합계 | 100 |
성분 | 함량(중량%) |
실시예 3 | 5.0 |
폴리솔베이트 60 | 1.5 |
솔비탄세스퀴올레이트 | 0.5 |
PEG60 경화피마자유 | 2.0 |
유동파라핀 | 10.0 |
스쿠알란 | 5.0 |
카프릴릭/카프릭트리글리세라이드 | 5.0 |
글리세린 | 5.0 |
부틸렌글리콜 | 3.0 |
프로필렌글리콜 | 3.0 |
트리에탄올아민 | 0.2 |
방부제, 색소, 향료 | 적량 |
정제수 | 잔량 |
합계 | 100 |
성분 | 함량(중량%) |
실시예3 | 5.0 |
밀납 | 10.0 |
폴리솔베이트 60 | 1.5 |
솔비탄세스퀴올레이트 | 0.8 |
PEG60 경화피마자유 | 2.0 |
유동파라핀 | 40.0 |
스쿠알란 | 5.0 |
카프릴릭/카프릭트리글리세라이드 | 4.0 |
글리세린 | 5.0 |
부틸렌글리콜 | 3.0 |
프로필렌글리콜 | 3.0 |
트리에탄올아민 | 0.2 |
방부제, 색소, 향료 | 적량 |
정제수 | 잔량 |
합계 | 100 |
성분 | 함량(중량%) |
실시예 3 | 5.0 |
폴리비닐알콜 | 13.0 |
소듐카르복시메틸셀룰로오스 | 0.2 |
글리세린 | 5.0 |
알란토인 | 0.1 |
에탄올 | 6.0 |
PEG 12 노닐페닐에테르 | 0.3 |
폴리솔베이트 60 | 0.3 |
방부제, 색소, 향료 | 적량 |
정제수 | 잔량 |
합계 | 100 |
피부 주름 평가 기준 | 점수 |
극히 심하게 악화 | -3 |
악화 | -2 |
약간 악화 | -1 |
변화 없음 | 0 |
약간 개선 | 1 |
개선 | 2 |
매우 개선 | 3 |
구분 | 평균주름 개선정도(ΔW) | |
T0 | T12 | |
피검자 1 | 0 | 2 |
피검자 2 | 0 | 2 |
피검자 3 | 0 | 3 |
피검자 4 | 0 | 1 |
피검자 5 | 0 | 2 |
피검자 6 | 0 | 2 |
피검자 7 | 0 | 2 |
피검자 8 | 0 | 3 |
피검자 9 | 0 | 1 |
피검자 10 | 0 | 3 |
ΔW(T12-T0) | 2.1 |
구분 | 평균주름 개선정도(ΔW) | |
T0 | T12 | |
피검자 1 | 0 | 2 |
피검자 2 | 0 | 3 |
피검자 3 | 0 | 3 |
피검자 4 | 0 | 2 |
피검자 5 | 0 | 2 |
피검자 6 | 0 | 2 |
피검자 7 | 0 | 2 |
피검자 8 | 0 | 2 |
피검자 9 | 0 | 1 |
피검자 10 | 0 | 3 |
ΔW(T12-T0) | 2.0 |
Claims (3)
- 복분자(Rubus coreanus) 추출물을 유효성분으로 함유하는 피부 주름 개선용 화장료 조성물.
- 제 1항에 있어서, 상기 복분자 추출물이 복분자를 추출하기 전 포제 처리하는 것임을 특징으로 하는 피부 주름 개선용 화장료 조성물.
- 제 1항 또는 제 2항에 있어서, 상기 복분자 추출물을 조성물 총 중량에 대하여 0.0001~30중량%의 양으로 함유하는 것을 특징으로 하는 피부 주름 개선용 화장료 조성물.
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/381,784 US20120107431A1 (en) | 2009-06-30 | 2010-06-25 | Cosmetic composition containing a rubus coreanus extract for diminishing skin wrinkles |
JP2012517393A JP5889185B2 (ja) | 2009-06-30 | 2010-06-25 | トックリイチゴ酒蒸抽出物の製造方法 |
CN2010800291473A CN102470096B (zh) | 2009-06-30 | 2010-06-25 | 一种含有覆盆子提取物的改善皮肤皱纹用化妆品组合物 |
HK12109663.3A HK1168799A1 (en) | 2009-06-30 | 2012-09-28 | Cosmetic composition containing a rubus coreanus extract for diminishing skin wrinkles |
US13/778,176 US9198945B2 (en) | 2009-06-25 | 2013-02-27 | Cosmetic compositoin containing a rubus coreanus extract for diminishing skin wrinkles |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2009-0058901 | 2009-06-30 | ||
KR20090058901 | 2009-06-30 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/381,784 A-371-Of-International US20120107431A1 (en) | 2009-06-25 | 2010-06-25 | Cosmetic composition containing a rubus coreanus extract for diminishing skin wrinkles |
US13/778,176 Division US9198945B2 (en) | 2009-06-25 | 2013-02-27 | Cosmetic compositoin containing a rubus coreanus extract for diminishing skin wrinkles |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2011002179A2 true WO2011002179A2 (ko) | 2011-01-06 |
WO2011002179A3 WO2011002179A3 (ko) | 2011-05-19 |
Family
ID=43411567
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2010/004144 WO2011002179A2 (ko) | 2009-06-25 | 2010-06-25 | 복분자 추출물을 함유하는 피부 주름 개선용 화장료 조성물 |
Country Status (6)
Country | Link |
---|---|
US (2) | US20120107431A1 (ko) |
JP (1) | JP5889185B2 (ko) |
KR (1) | KR101736775B1 (ko) |
CN (1) | CN102470096B (ko) |
HK (1) | HK1168799A1 (ko) |
WO (1) | WO2011002179A2 (ko) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102017240B1 (ko) * | 2018-08-23 | 2019-09-02 | 주식회사 하울바이오 | Snare 복합체를 억제하는 항-vamp2 항체 및 이의 용도 |
US11224564B2 (en) | 2018-06-29 | 2022-01-18 | Hoseo University Academic Cooperation Foundation | Composition comprising erigeron annuus flower essential oil for prevention and treatment of neuromuscular disease |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8617568B2 (en) * | 2007-07-10 | 2013-12-31 | Medy-Tox, Inc. | Pharmaceutical liquid composition of botulinum toxin with improved stability |
CN103110560A (zh) * | 2012-12-14 | 2013-05-22 | 吴江市德佐日用化学品有限公司 | 一种修复型护手霜的制备方法 |
KR101314680B1 (ko) * | 2013-01-04 | 2013-10-04 | 주식회사 다솔 | 복분자 파우더를 함유한 화장품 조성물 |
US9480731B2 (en) * | 2013-12-12 | 2016-11-01 | Medy-Tox, Inc. | Long lasting effect of new botulinum toxin formulations |
CN109803673A (zh) | 2016-09-13 | 2019-05-24 | 阿勒根公司 | 非蛋白质梭菌毒素组合物 |
KR102249419B1 (ko) * | 2018-11-15 | 2021-05-07 | 김영배 | 복분자유를 유효성분으로 함유하는 피부장벽 기능 개선용 조성물 |
KR102310943B1 (ko) | 2019-05-16 | 2021-10-07 | 재단법인 포항테크노파크 | 산딸기 추출물 분말 및 산딸기씨 분말을 함유하는 바디 스크랩 화장료 조성물의 제조방법 |
KR102297991B1 (ko) | 2019-10-11 | 2021-09-07 | 주식회사 하울바이오 | SNARE 복합체를 억제하는 항-Syntaxin 1A 항체 및 이의 용도 |
KR102274841B1 (ko) | 2019-10-16 | 2021-07-12 | 주식회사 하울바이오 | Snare 복합체를 억제하는 항-snap 25 항체 및 이의 용도 |
KR102367726B1 (ko) * | 2019-11-01 | 2022-02-25 | 동신대학교산학협력단 | 미성숙 복분자 추출물을 이용한 피부 주름 개선용 조성물 |
KR102561292B1 (ko) | 2022-05-20 | 2023-07-27 | 한도숙 | 피부 투과성을 향상시킨 신경전달물질 펜타펩타이드를 포함하는 주름 개선용 화장료 조성물 및 이의 제조방법 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20070044280A (ko) * | 2005-10-24 | 2007-04-27 | 금산고려홍삼 주식회사 | 황토와 홍삼 성분이 함유된 미용팩 |
KR20080008491A (ko) * | 2006-07-20 | 2008-01-24 | 주식회사 참 존 | 복분자 발효물 및 이를 포함하는 조성물 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0873342A (ja) * | 1994-09-05 | 1996-03-19 | Ichimaru Pharcos Co Ltd | 覆盆子抽出物含有皮膚外用剤または浴用剤 |
US20030152545A1 (en) * | 2000-12-01 | 2003-08-14 | Park Hyo Suk | Topical liquid composition for promoting hair growth and process of manufacturing thereof |
JP2002241299A (ja) * | 2001-02-13 | 2002-08-28 | Ichimaru Pharcos Co Ltd | メイラード反応修復剤 |
CN1245953C (zh) * | 2004-05-17 | 2006-03-22 | 刘贤英 | 一种中药生物祛皱嫩肤化妆品及其制备工艺 |
JP2007186457A (ja) * | 2006-01-13 | 2007-07-26 | Ichimaru Pharcos Co Ltd | トリプターゼ活性阻害剤およびその利用 |
JP4800049B2 (ja) * | 2006-01-31 | 2011-10-26 | 一丸ファルコス株式会社 | mTORを活性化する製剤及びmTORを活性化する方法 |
-
2010
- 2010-06-25 WO PCT/KR2010/004144 patent/WO2011002179A2/ko active Application Filing
- 2010-06-25 US US13/381,784 patent/US20120107431A1/en not_active Abandoned
- 2010-06-25 JP JP2012517393A patent/JP5889185B2/ja active Active
- 2010-06-25 CN CN2010800291473A patent/CN102470096B/zh active Active
- 2010-06-25 KR KR1020100060309A patent/KR101736775B1/ko active IP Right Grant
-
2012
- 2012-09-28 HK HK12109663.3A patent/HK1168799A1/xx unknown
-
2013
- 2013-02-27 US US13/778,176 patent/US9198945B2/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20070044280A (ko) * | 2005-10-24 | 2007-04-27 | 금산고려홍삼 주식회사 | 황토와 홍삼 성분이 함유된 미용팩 |
KR20080008491A (ko) * | 2006-07-20 | 2008-01-24 | 주식회사 참 존 | 복분자 발효물 및 이를 포함하는 조성물 |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11224564B2 (en) | 2018-06-29 | 2022-01-18 | Hoseo University Academic Cooperation Foundation | Composition comprising erigeron annuus flower essential oil for prevention and treatment of neuromuscular disease |
KR102017240B1 (ko) * | 2018-08-23 | 2019-09-02 | 주식회사 하울바이오 | Snare 복합체를 억제하는 항-vamp2 항체 및 이의 용도 |
WO2020040481A1 (ko) * | 2018-08-23 | 2020-02-27 | 주식회사 하울바이오 | Snare 복합체를 억제하는 항-vamp2 항체 및 이의 용도 |
CN111868092A (zh) * | 2018-08-23 | 2020-10-30 | 哈坞生物科技株式会社 | 抑制snare复合体的抗vamp2抗体及其用途 |
US11958897B2 (en) | 2018-08-23 | 2024-04-16 | Hauul Bio | Anti-VAMP2 antibody for inhibiting snare complex and use thereof |
Also Published As
Publication number | Publication date |
---|---|
US9198945B2 (en) | 2015-12-01 |
CN102470096B (zh) | 2013-12-18 |
US20130171282A1 (en) | 2013-07-04 |
WO2011002179A3 (ko) | 2011-05-19 |
HK1168799A1 (en) | 2013-01-11 |
CN102470096A (zh) | 2012-05-23 |
JP2012532097A (ja) | 2012-12-13 |
US20120107431A1 (en) | 2012-05-03 |
JP5889185B2 (ja) | 2016-03-22 |
KR20110001915A (ko) | 2011-01-06 |
KR101736775B1 (ko) | 2017-05-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2011002179A2 (ko) | 복분자 추출물을 함유하는 피부 주름 개선용 화장료 조성물 | |
CN108670943A (zh) | 一种保湿、美白、淡斑植物提取物组合物 | |
CN106977586B (zh) | 一种促进组织修复的美洲大蠊新多肽及应用 | |
KR20070069204A (ko) | 이상 단백질 제거용 조성물 | |
KR20090056397A (ko) | 복방 생약 추출물을 유효성분으로 함유하는 피부 외용제조성물 | |
KR20100135871A (ko) | 섬유모세포의 증식 및/또는 활성을 자극하는 활성 성분 | |
EA021777B1 (ru) | Композиция, содержащая экстракт венериной мухоловки dionaea muscipula, для косметической обработки кожи и придатков кожи | |
KR20200063855A (ko) | 밀크씨슬 꽃 추출물을 유효성분으로 포함하는 멜라닌 생성 촉진용 조성물 | |
JP2001163794A (ja) | ヒアルロン酸産生促進剤および皮膚外用剤 | |
KR20130010250A (ko) | 허니부쉬 추출물 또는 이의 발효액을 유효성분으로 함유하는 피부 주름 개선용 조성물 | |
JP2001158728A (ja) | ヒアルロン酸産生促進剤および皮膚外用剤 | |
KR102104214B1 (ko) | 포타슘 알룸을 포함하는 화장료 조성물 | |
KR20110008396A (ko) | 편백잎 추출물을 함유하는 피부 주름 개선용 화장료 조성물 | |
CN111484549B (zh) | 一种美洲大蠊组织修复因子pa1及其应用 | |
KR101650020B1 (ko) | 스노우베리 추출물을 함유하는 피부 주름 개선용 화장료 조성물 | |
JP5863225B2 (ja) | 美肌用組成物 | |
KR101065356B1 (ko) | 동백박(동백종실 껍질 분말) 및 그 추출물의 이용 | |
KR20140026819A (ko) | 진피 및 우슬의 혼합 추출물을 함유하는 피부장벽강화용 조성물 | |
JPH01102011A (ja) | 皮膚化粧料 | |
KR20130102712A (ko) | 따나카 발효 추출물을 이용한 열노화 방지 및 피부 개선 조성물 | |
WO2022169066A1 (ko) | 금화규 유래 콜라겐아미노산을 이용한 기능성 콜라겐 조성물 | |
KR101290790B1 (ko) | 한방 나노좀을 함유하는 피부트러블 개선 및 진정효과를 갖는 화장료 조성물 | |
KR101214344B1 (ko) | 쌀겨와 감초발효추출물을 포함하는 화장료 조성물 | |
WO2019164090A1 (ko) | 앉은 부채 추출물 또는 이의 분획물을 유효성분으로 포함하는 주름 개선용 조성물 | |
KR20110089626A (ko) | 식물 추출물을 포함하는 화장료 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201080029147.3 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10794314 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012517393 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13381784 Country of ref document: US |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 10794314 Country of ref document: EP Kind code of ref document: A2 |